Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00200343 |
Recruitment Status :
Completed
First Posted : September 20, 2005
Results First Posted : November 7, 2011
Last Update Posted : March 12, 2012
|
Sponsor:
Mitsubishi Tanabe Pharma Corporation
Information provided by:
Mitsubishi Tanabe Pharma Corporation
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double; Primary Purpose: Treatment |
Condition |
Chronic Hepatitis C |
Interventions |
Drug: Ursodeoxycholic acid 150mg / day Drug: Ursodeoxycholic acid 600mg / day Drug: Ursodeoxycholic acid 900mg / day |
Enrollment | 596 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Baseline Characteristics
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title:
Clinical Trials, Information Desk
Organization:
Mitsubishi Tanabe Pharma Corporation
ClinicalTrials.gov Identifier: | NCT00200343 History of Changes |
Other Study ID Numbers: |
MT711-01 |
First Submitted: | September 12, 2005 |
First Posted: | September 20, 2005 |
Results First Submitted: | August 17, 2011 |
Results First Posted: | November 7, 2011 |
Last Update Posted: | March 12, 2012 |